PEN:NYE-Penumbra Inc. (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 296

Change

+4.18 (+1.43)%

Market Cap

USD 2.10B

Volume

0.38M

Analyst Target

USD 252.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-02 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-0.22 (-0.17%)

USD 220.05B
MDT Medtronic PLC

-1.40 (-1.65%)

USD 106.32B
STE STERIS plc

-0.51 (-0.23%)

USD 22.11B
ZBH Zimmer Biomet Holdings Inc

-11.90 (-11.62%)

USD 20.08B
SNN Smith & Nephew SNATS Inc

-0.25 (-0.87%)

USD 11.31B
GMED Globus Medical

-1.41 (-1.96%)

USD 9.77B
BIO Bio-Rad Laboratories Inc

+3.85 (+1.63%)

USD 6.94B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 6.39B
GKOS Glaukos Corp

-0.75 (-0.86%)

USD 5.15B
INSP Inspire Medical Systems Inc

-1.07 (-0.67%)

USD 4.39B

ETFs Containing PEN

DOCT:SW L&G Healthcare Breakthrou.. 2.12 % 0.00 %

N/A

USD 0.06B
DOCG:LSE L&G Healthcare Breakthrou.. 2.03 % 0.00 %

N/A

USD 0.06B
DOCT:LSE L&G Healthcare Breakthrou.. 2.03 % 0.00 %

N/A

USD 0.06B
BWZ SPDR® Bloomberg Short Te.. 0.00 % 0.35 %

+0.08 (+0.00%)

N/A
ETHO Amplify ETF Trust 0.00 % 0.45 %

-0.25 (0.00%)

USD 0.18B
FNY First Trust Mid Cap Growt.. 0.00 % 0.70 %

-0.22 (0.00%)

USD 0.35B
FXH First Trust Health Care A.. 0.00 % 0.63 %

-0.56 (0.00%)

USD 0.89B
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

-1.45 (0.00%)

USD 0.16B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.64% 94% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.64% 94% A 96% N/A
Trailing 12 Months  
Capital Gain 41.93% 94% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.93% 94% A 94% A
Trailing 5 Years  
Capital Gain 73.48% 76% C+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.48% 76% C+ 56% F
Average Annual (5 Year Horizon)  
Capital Gain 8.43% 57% F 65% D
Dividend Return 8.43% 54% F 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.47% 37% F 18% F
Risk Adjusted Return 18.55% 66% D+ 37% F
Market Capitalization 2.10B 83% B 87% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 770.42 5% 1%
Price/Book Ratio 9.32 14% 9%
Price / Cash Flow Ratio 63.68 3% 3%
Price/Free Cash Flow Ratio 230.75 3% 1%
Management Effectiveness  
Return on Equity 1.20% 66% 31%
Return on Invested Capital 0.21% 47% 27%
Return on Assets 4.84% 83% 73%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector